These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26862758)

  • 1. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
    McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
    PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.
    Arias MA; Van Roey GA; Tregoning JS; Moutaftsi M; Coler RN; Windish HP; Reed SG; Carter D; Shattock RJ
    PLoS One; 2012; 7(7):e41144. PubMed ID: 22829921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations.
    Pattani A; McKay PF; Garland MJ; Curran RM; Migalska K; Cassidy CM; Malcolm RK; Shattock RJ; McCarthy HO; Donnelly RF
    J Control Release; 2012 Sep; 162(3):529-37. PubMed ID: 22960496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.
    Poteet E; Lewis P; Li F; Zhang S; Gu J; Chen C; Ho SO; Do T; Chiang S; Fujii G; Yao Q
    PLoS One; 2015; 10(8):e0136862. PubMed ID: 26312747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.
    McKay PF; Mann JF; Pattani A; Kett V; Aldon Y; King D; Malcolm RK; Shattock RJ
    J Control Release; 2017 Mar; 249():74-83. PubMed ID: 28115243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.
    McKay PF; Cope AV; Mann JF; Joseph S; Esteban M; Tatoud R; Carter D; Reed SG; Weber J; Shattock RJ
    PLoS One; 2014; 9(1):e84707. PubMed ID: 24465426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routing dependent immune responses after experimental R848-adjuvated vaccination.
    van Aalst S; Jansen MAA; Ludwig IS; van der Zee R; van Eden W; Broere F
    Vaccine; 2018 Mar; 36(11):1405-1413. PubMed ID: 29409680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.
    Cristillo AD; Ferrari MG; Hudacik L; Lewis B; Galmin L; Bowen B; Thompson D; Petrovsky N; Markham P; Pal R
    J Gen Virol; 2011 Jan; 92(Pt 1):128-40. PubMed ID: 21169215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
    Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
    Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adjuvant GLA-AF enhances human intradermal vaccine responses.
    Carter D; van Hoeven N; Baldwin S; Levin Y; Kochba E; Magill A; Charland N; Landry N; Nu K; Frevol A; Ashman J; Sagawa ZK; Beckmann AM; Reed SG
    Sci Adv; 2018 Sep; 4(9):eaas9930. PubMed ID: 30221194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
    Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.
    Moody MA; Santra S; Vandergrift NA; Sutherland LL; Gurley TC; Drinker MS; Allen AA; Xia SM; Meyerhoff RR; Parks R; Lloyd KE; Easterhoff D; Alam SM; Liao HX; Ward BM; Ferrari G; Montefiori DC; Tomaras GD; Seder RA; Letvin NL; Haynes BF
    J Virol; 2014 Mar; 88(6):3329-39. PubMed ID: 24390332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine.
    Pouliot K; Buglione-Corbett R; Marty-Roix R; Montminy-Paquette S; West K; Wang S; Lu S; Lien E
    Vaccine; 2014 Sep; 32(39):5049-56. PubMed ID: 25045815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.
    Cosgrove CA; Lacey CJ; Cope AV; Bartolf A; Morris G; Yan C; Baden S; Cole T; Carter D; Brodnicki E; Shen X; Joseph S; DeRosa SC; Peng L; Yu X; Ferrari G; Seaman M; Montefiori DC; Frahm N; Tomaras GD; Stöhr W; McCormack S; Shattock RJ
    PLoS One; 2016; 11(5):e0152038. PubMed ID: 27159166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
    Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
    Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.